Julia Tonini

Phase 1b Study of New Posaconazole Tablet for Prevention of Invasive Fungal Infections in High-Risk Patients with Neutropenia

Breakthrough invasive fungal disease in patients receiving posaconazole primary prophylaxis: a 4-year study

An Official ATS Clinical Practice Guideline: Interpretation of Exhaled Nitric Oxide Levels (F e _NO ) for Clinical Applications

Concerns about pharmacokinetic (PK) and pharmacokinetic-pharmacodynamic (PK-PD) studies in the new therapeutic area of COVID-19 infection

Exhaled Nitric Oxide Concentration Is Affected by Age, Height, and Race in Healthy 9- to 12-Year-Old Children

Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology

Flexible graphene bio-nanosensor for lactate

Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results

Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America

Serum posaconazole levels among haematological cancer patients taking extended release tablets is affected by body weight and diarrhoea: single centre retrospective analysis

25th Anniversary Article: The Evolution of Electronic Skin (E‐Skin): A Brief History, Design Considerations, and Recent Progress

Inflammation is a potential risk factor of voriconazole overdose in hematological patients

Exhaled nitric oxide in single and repetitive prolonged exercise

Effect of chronic intermittent hypoxia on exercise adaptations in healthy subjects

Therapeutic Drug Monitoring of Posaconazole in Allogeneic Hematopoietic Stem Cell Transplantation Patients Who Develop Gastrointestinal Graft-versus-Host Disease